We feel now is a pretty good time to analyse Iterum Therapeutics plc's Nasdaq Itrm business as it appears the...
Why Is Iterum Therapeutics plc Ordinary Share (ITRM) Stock Down Today?
Updated Nov 22, 2026 6:19 AM ET ยท Prev Close $0.07
This stock is down 57% today โ a major single-session selloff. Confirm volume stabilization and key support defense before entering.
Session Regime & Catalyst Assessment
68% Signal ConvictionIterum Therapeutics plc Ordinary Share Pulling Back 57.39% on 0.20x Relative Volume
Iterum Therapeutics plc Ordinary Share (ITRM) is pulling back 57.39% (-$0.04) to $0.03 on 0.20x average session volume. Relative to benchmarks, ITRM is lagging the S&P 500 by -53.75%. 14-day RSI stands at 25.9, keeping momentum in a oversold regime.
We feel now is a pretty good time to analyse Iterum Therapeutics plc's Nasdaq Itrm business as it appears the...
Price ($0.03) trades relative to 20-day SMA ($0.15) and 50-day SMA ($0.23).
Market & Sector Relative Strength
ITRM lagging the S&P 500 by -53.75%Options Flow & Execution Desk
Recent ITRM Catalyst Headlines
Verified WireDUBLIN and Chicago, March 27, 2026 Globe Newswire -- Iterum Therapeutics plc in Provisional Liquidation Nasdaq ITRM the Company or Iterum or we , a company focused on delivering next generation oral and IV antibiotics to
--Expanded Market Access and Patent Protection for Orlynvah --FDA correspondence regarding the use of Orlynvah as step-down therapy DUBLIN and Chicago, Feb. 13, 2026 Globe Newswire -- Iterum Therapeutics plc Nasdaq ITRM
Iterum Therapeutics PLC Itrm reports successful Orlinva launch amidst rising expenses and capital needs.
1โ3 Day Expected Range & Key Level
48% Follow-ThroughMonitor volume expansion above 1.5x RVOL around $0.03 (session support) for directional breakout confirmation.
Technical Regime (ITRM)
BEARISH MA TRENDRetail & Crowd Sentiment
BearishStockTwits messages indicate bullish sentiment towards $ITRM with traders expressing confidence in its potential growth and faster Irish High Court liquidation process. No recent news articles were available.
About Iterum Therapeutics plc Ordinary Share
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the โฆ
Get Instant ITRM Catalyst Alerts
Receive an email alert when ITRM triggers an unusual volume breakout, options sweep, or rating shift.
ITRM Session & Catalyst FAQ
Why is ITRM stock down today?
Iterum Therapeutics plc Ordinary Share (ITRM) is pulling back 57.39% (-$0.04) to $0.03 on 0.20x average session volume. Relative to benchmarks, ITRM is lagging the S&P 500 by -53.75%. 14-day RSI stands at 25.9, keeping momentum in a oversold regime.
Is ITRM stock a buy or sell right now?
Today's session carries a 68% catalyst conviction score on 0.20x relative volume (low participation). Our multi-factor model currently rates ITRM as HOLD. Review full valuation, quality, and timing signals on the ITRM Buy or Sell Decision Brief โ
What is ITRM's intrinsic value and expected trading range?
At $0.03, ITRM's modeled 1-to-3 session range is $0.03 โ $0.03, with a key inflection level at $0.03 (session support). Compare current price against multi-year cash flow projections in the ITRM Intrinsic Value & DCF Model โ and Market Cycle Phase Tracker โ
What do RSI and moving averages signal for ITRM?
RSI at 25.9 indicates oversold conditions โ watch for mean-reversion support. ITRM trades at $0.03 relative to its 20-day SMA ($0.15) and 50-day SMA ($0.23), reflecting a bearish moving-average structure.
Tradestie Flagship Research & Market Hubs
Live institutional catalyst tape ranking liquid gainers, losers, options sweeps, and RVOL surges.
Track spot H100/B200 compute rental rates and frontier LLM inference token economics.
Wafer yield, CoWoS packaging, and HBM bill-of-materials teardown models across AI accelerators.
Monitor engineering velocity and upstream foundry wafer demand inflections across tech leaders.
Live conviction tracking, invalidation guardrails, and thesis health checks on flagship ideas.
Backtest-validated unusual options positioning and open-interest accumulation setups.
Daily ranked quantitative leaderboard with audited forward-return track record vs S&P 500.
High-yield, quality-screened cash-secured put and put-spread income candidates.